論文 - 詳細
| RRC ID | 51963 |
|---|---|
| 著者 | Kurinami H, Shimamura M, Nakagami H, Shimizu H, Koriyama H, Kawano T, Wakayama K, Mochizuki H, Rakugi H, Morishita R. |
| タイトル | A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke. |
| ジャーナル | Sci Rep |
| Abstract |
The enhanced receptor activator of nuclear factor-κB (NFκB) ligand (RANKL) and its receptor (RANK) signal have been reported to attenuate ischemic brain injury through inhibition of Toll-like receptor (TLR) 4-mediated inflammation. However, augmentation of the RANKL/RANK signal also accelerates osteoporosis, which is a potential problem in clinical use of RANKL. Therefore, we developed novel peptides, microglial healing peptides (MHPs), which were based on the DE and/or EF loop of RANKL. Among them, MHP1 was the most effective inhibitor of TLR4-induced inflammations in microglia/macrophages. The effects depended on RANK, as confirmed by knockdown experiments. In contrast to RANKL, MHP1 did not stimulate osteoclast differentiation. Unexpectedly, MHP1 inhibited RANKL-induced osteoclast differentiation. These findings suggested that MHP1 was a partial agonist of RANKL, and administration of MHP1 attenuated ischemic injury by decreasing inflammation. MHP1 could be a novel therapeutic agent for treating ischemic stroke. |
| 巻・号 | 6 |
| ページ | 38062 |
| 公開日 | 2016-11-29 |
| DOI | 10.1038/srep38062 |
| PII | srep38062 |
| PMID | 27897273 |
| PMC | PMC5126682 |
| MeSH | Animals Brain Ischemia Cell Differentiation / drug effects Mice Osteoclasts / metabolism Osteoclasts / pathology Peptides / chemistry Peptides / pharmacology* RANK Ligand / agonists* RANK Ligand / metabolism RAW 264.7 Cells Stroke / drug therapy* Stroke / metabolism Stroke / pathology Toll-Like Receptor 4 / antagonists & inhibitors Toll-Like Receptor 4 / metabolism |
| IF | 3.998 |
| 引用数 | 10 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 9 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | MG6(RCB2403) |